Loading...
Header Logo
Keywords
Last Name
Institution

JOHN F WARD

TitleAssociate Professor
InstitutionMD Anderson
DepartmentUrology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, Wood BJ, Gorin MA, Sidana A, Ghai S, Tay KJ, Ward JF, Sanchez-Salas R, Muller BG, Malavaud B, Mozer P, Crouzet S, Choyke PL, Ukimura O, Rastinehad AR, Pinto PA. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. Eur Urol. 2020 Jun 09. PMID: 32532513.
      View in: PubMed
    2. Shapiro DD, Gregg JR, Lim AH, Nogueras-González GM, Choi H, Kang HC, Inguillo IA, Chapin BF, Davis JW, Ward JF. Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance. BJU Int. 2020 May 01. PMID: 32357283.
      View in: PubMed
    3. Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, Bathala TK, Bittencourt LK, Booker MT, Braxton VG, Carroll PR, Casalino DD, Chang SD, Coakley FV, Dhatt R, Eberhardt SC, Foster BR, Froemming AT, Fütterer JJ, Ganeshan DM, Gertner MR, Mankowski Gettle L, Ghai S, Gupta RT, Hahn ME, Houshyar R, Kim C, Kim CK, Lall C, Margolis DJA, McRae SE, Oto A, Parsons RB, Patel NU, Pinto PA, Polascik TJ, Spilseth B, Starcevich JB, Tammisetti VS, Taneja SS, Turkbey B, Verma S, Ward JF, Warlick CA, Weinberger AR, Yu J, Zagoria RJ, Rosenkrantz AB. Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology. 2020 Jul; 296(1):76-84. PMID: 32315265.
      View in: PubMed
    4. Gregg JR, Davis JW, Reichard C, Wang X, Achim M, Chapin BF, Pisters L, Pettaway C, Ward JF, Choi S, Nguyen QN, Kuban D, Babaian R, Troncoso P, Madsen LT, Logothetis C, Kim J. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort. Urology. 2020 Apr; 138:91-97. PMID: 31899230.
      View in: PubMed
    5. Li R, Duplisea JJ, Petros FG, González GMN, Tu SM, Karam JA, Huynh TT, Ward JF. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Eur Urol Oncol. 2019 Mar 29. PMID: 31412007.
      View in: PubMed
    6. Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF. Detection and Treatment of Primary Prostatic Melanoma. Urology. 2019 01; 123:16-19. PMID: 30195014.
      View in: PubMed
    7. Altok M, Kim B, Patel BB, Shih YT, Ward JF, McRae SE, Chapin BF, Pisters LL, Pettaway CA, Kim J, Demirel HC, Davis JW. Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532. PMID: 29988098.
      View in: PubMed
    8. Reichard CA, Gregg JR, Achim MF, Aparicio AM, Pettaway CA, Pisters LL, Ward JF, Davis JW, Chapin BF. Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes. Eur Urol. 2018 08; 74(2):140-143. PMID: 29656854.
      View in: PubMed
    9. Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA. Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU Int. 2018 04; 121(4):540-548. PMID: 28941030.
      View in: PubMed
    10. Li R, Petros FG, Davis CJ, Ward JF. Characterization of Glomus Tumors of the Kidney. Clin Genitourin Cancer. 2017 Sep 07. PMID: 28967505.
      View in: PubMed
    11. Basourakos SP, Davis JW, Chapin BF, Ward JF, Pettaway CA, Pisters LL, Navai N, Achim MF, Wang X, Chen HC, Choi S, Kuban D, Troncoso P, Hanash S, Thompson TC, Kim J. Baseline and longitudinal plasma caveolin-1 level as a biomarker in active surveillance for early-stage prostate cancer. BJU Int. 2018 01; 121(1):69-76. PMID: 28710901.
      View in: PubMed
    12. Metcalfe MJ, Troncoso P, Guo CC, Chen HC, Bozkurt Y, Ward JF, Pisters LL. Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes. Can Urol Assoc J. 2017 Jul; 11(7):E277-E284. PMID: 28761588.
      View in: PubMed
    13. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412.
      View in: PubMed
    14. Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward JF. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients. BJU Int. 2017 06; 119(6):896-904. PMID: 28063191.
      View in: PubMed
    15. Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, Logothetis CJ, Pisters LL, Tu SM. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 2016 Dec 27; 7(52):86280-86289. PMID: 27861143.
      View in: PubMed
    16. Kenney PA, Nawaf CB, Mustafa M, Wen S, Wszolek MF, Pettaway CA, Ward JF, Davis JW, Pisters LL. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol. 2016 Jun; 23(3):8271-7. PMID: 27347619.
      View in: PubMed
    17. Pearce SM, Golan S, Gorin MA, Luckenbaugh AN, Williams SB, Ward JF, Montgomery JS, Hafez KS, Weizer AZ, Pierorazio PM, Allaf ME, Eggener SE. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. Eur Urol. 2017 03; 71(3):476-482. PMID: 27234998.
      View in: PubMed
    18. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93. PMID: 27322462.
      View in: PubMed
    19. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SC, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. 2016 06 15; 122(12):1836-43. PMID: 27018785.
      View in: PubMed
    20. Williams SB, Ward JF. Re: Jan P. Radtke, Constantin Schwab, Maya B. Wolf, et al. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.12.052. Eur Urol. 2016 09; 70(3):e77-8. PMID: 26988610.
      View in: PubMed
    21. Mustafa M, Delacroix S, Ward JF, Pisters L. The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World J Surg Oncol. 2015 Dec 21; 13:340. PMID: 26691335.
      View in: PubMed
    22. Ward JF, Eggener SE. Active surveillance monitoring: the role of novel biomarkers and imaging. Asian J Androl. 2015 Nov-Dec; 17(6):882-4; discussion 883. PMID: 26112488.
      View in: PubMed
    23. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer. 2016 Apr; 14(2):130-8. PMID: 26558524.
      View in: PubMed
    24. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross ME, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ. Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495.e1-7. PMID: 26231310.
      View in: PubMed
    25. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 07; 118(1):68-76. PMID: 26059275.
      View in: PubMed
    26. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 2016 Mar; 117(3):469-77. PMID: 25714186.
      View in: PubMed
    27. Skolnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD, Nelson NR, Stocchetti N. A clinical trial of progesterone for severe traumatic brain injury. N Engl J Med. 2014 Dec 25; 371(26):2467-76. PMID: 25493978.
      View in: PubMed
    28. Subbiah V, Meric-Bernstam F, Mills GB, Shaw KR, Bailey AM, Rao P, Ward JF, Pagliaro LC. Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRß/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. J Hematol Oncol. 2014 Aug 01; 7:52. PMID: 25085632.
      View in: PubMed
    29. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic. J Natl Compr Canc Netw. 2014 Jul; 12(7):993-8. PMID: 24994920.
      View in: PubMed
    30. Valerio M, Emberton M, Barret E, Eberli D, Eggener SE, Ehdaie B, Jichlinski P, Ward JF, Ahmed HU. Health technology assessment in evolution - focal therapy in localised prostate cancer. Expert Rev Anticancer Ther. 2014 Nov; 14(11):1359-67. PMID: 24965212.
      View in: PubMed
    31. Reis LO, Billis A, Zequi SC, Tobias-Machado M, Viana P, Cerqueira M, Ward JF. Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts ("ICE"). Aging Male. 2014 Jun; 17(2):66-71. PMID: 24597940.
      View in: PubMed
    32. Ward JF, DiBlasio CJ, Williams C, Given R, Jones JS. Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. BJU Int. 2014 May; 113(5):714-8. PMID: 24112776.
      View in: PubMed
    33. van den Bos W, Muller BG, Ahmed H, Bangma CH, Barret E, Crouzet S, Eggener SE, Gill IS, Joniau S, Kovacs G, Pahernik S, de la Rosette JJ, Rouvière O, Salomon G, Ward JF, Scardino PT. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. Eur Urol. 2014 Jun; 65(6):1078-83. PMID: 24444476.
      View in: PubMed
    34. Ward JF, Pisters LL. Considerations for patient selection for focal therapy. Ther Adv Urol. 2013 Dec; 5(6):330-7. PMID: 24294291.
      View in: PubMed
    35. Matin SF, Cormier JN, Ward JF, Pisters LL, Wood CG, Dinney CP, Royal RE, Huang X, Pettaway CA. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU Int. 2013 Jun; 111(7):1068-74. PMID: 23551693.
      View in: PubMed
    36. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol. 2013 Jul; 190(1):64-9. PMID: 23416644.
      View in: PubMed
    37. Watson JC, Tye G, Ward JD. Delayed repair of myelomeningoceles. World Neurosurg. 2014 Feb; 81(2):428-30. PMID: 23313260.
      View in: PubMed
    38. Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganzer R, Pasticier G, Thuroff S, Ward JF. Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. Prostate Cancer Prostatic Dis. 2012 Sep; 15(3):256-9. PMID: 22487909.
      View in: PubMed
    39. Leibovici D, Chiong E, Pisters LL, Guo CC, Ward JF, Andino L, Prokhorova IN, Troncoso P. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol. 2012 Jul; 188(1):98-102. PMID: 22578724.
      View in: PubMed
    40. Ward JF, Rewcastle JC, Ukimura O, Gill IS. Focal therapy for the treatment of localized prostate cancer: a potential therapeutic paradigm shift awaiting better imaging. Curr Opin Urol. 2012 Mar; 22(2):104-8. PMID: 22273756.
      View in: PubMed
    41. Pisters PW, Pettaway CA, Liu P, Matin SF, Ward JF, Leibovici D. Is transureteroureterostomy performed during multi-organ resection for non-urothelial malignancy safe and effective? J Surg Oncol. 2012 Jul 01; 106(1):62-5. PMID: 22259198.
      View in: PubMed
    42. Shih YC, Ward JF, Pettaway CA, Xu Y, Matin SF, Davis JW, Thompson BP, Elting LS. Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health. 2012 Mar-Apr; 15(2):367-75. PMID: 22433769.
      View in: PubMed
    43. Ward JF, Jones JS. Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int. 2012 Jun; 109(11):1648-54. PMID: 22035200.
      View in: PubMed
    44. Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG. J Surg Res. 2012 Jul; 176(1):147-53. PMID: 22099584.
      View in: PubMed
    45. Dhar N, Ward JF, Cher ML, Jones JS. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int. 2011 Aug; 108(4):508-12. PMID: 21722288.
      View in: PubMed
    46. Ward JF. High-intensity focused ultrasound for therapeutic tissue ablation in surgical oncology. Surg Oncol Clin N Am. 2011 Apr; 20(2):389-407, ix. PMID: 21377590.
      View in: PubMed
    47. Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. BJU Int. 2011 Oct; 108(8 Pt 2):E196-201. PMID: 21332907.
      View in: PubMed
    48. Ward JF. Prostate cancer: HIFU is effective, but associated morbidity still remains unclear. Nat Rev Urol. 2010 Nov; 7(11):597-8. PMID: 21068758.
      View in: PubMed
    49. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budäus L, Fisch M, Huland H, Graefen M, Haese A. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011 Jan; 59(1):96-105. PMID: 20980098.
      View in: PubMed
    50. Delacroix SE, Ward JF. Prostate cancer multifocality: impact on cancer biology and treatment recommendations. Panminerva Med. 2010 Sep; 52(3):209-16. PMID: 21045777.
      View in: PubMed
    51. Stafford RJ, Shetty A, Elliott AM, Klumpp SA, McNichols RJ, Gowda A, Hazle JD, Ward JF. Magnetic resonance guided, focal laser induced interstitial thermal therapy in a canine prostate model. J Urol. 2010 Oct; 184(4):1514-20. PMID: 20727549.
      View in: PubMed
    52. Ward JF. Contemporary outcomes of focal therapy in prostate cancer: what do we know so far... World J Urol. 2010 Oct; 28(5):593-7. PMID: 20680294.
      View in: PubMed
    53. Ward JF, Jones JS. Classification system: organ preserving treatment for prostate cancer. Urology. 2010 Jun; 75(6):1258-60. PMID: 20080292.
      View in: PubMed
    54. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients predicted to have low-volume/low-grade prostate cancer diagnosed by extended-core biopsies: an analysis of volume and zonal distribution of tumour foci. BJU Int. 2010 May; 105(10):1386-91. PMID: 19888979.
      View in: PubMed
    55. Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, Izawa J, Ward JF, Scott SM, Madsen L, Spiess PE, Leibovich BC. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol. 2009 Aug; 182(2):517-25; discussion 525-7. PMID: 19524984.
      View in: PubMed
    56. Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. 2009 Oct; 104(8):1058-62. PMID: 19388986.
      View in: PubMed
    57. Ward JF. Editorial comment on: Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol. 2010 Mar; 57(3):444-5. PMID: 19303198.
      View in: PubMed
    58. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int. 2009 Aug; 104(4):490-7. PMID: 19220260.
      View in: PubMed
    59. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2729-34. PMID: 19202079.
      View in: PubMed
    60. Ward JF, Pagliaro LC, Pisters LL. Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer. 2008 Nov-Dec; 32(6):242-71. PMID: 19064119.
      View in: PubMed
    61. Moul JW, Ward JF. Management of the patient with a rising PSA alone. Hematol Oncol Clin North Am. 2006 Aug; 20(4):897-908. PMID: 16861121.
      View in: PubMed
    62. Ward JF. Can PSA velocity serve as a surrogate endpoint in trials of hormone-refractory, metastatic prostate cancer? Nat Clin Pract Urol. 2006 Jun; 3(6):310-1. PMID: 16763642.
      View in: PubMed
    63. Ward JF, Moul JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clin Prostate Cancer. 2005 Jun; 4(1):38-44. PMID: 15992460.
      View in: PubMed
    64. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May; 15(3):187-95. PMID: 15815196.
      View in: PubMed
    65. Ward JF, Moul JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Curr Opin Urol. 2005 May; 15(3):181-6. PMID: 15815195.
      View in: PubMed
    66. Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol. 2005 Apr; 173(4):1156-60. PMID: 15758726.
      View in: PubMed
    67. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6. PMID: 15794776.
      View in: PubMed
    68. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol. 2005 Apr; 2(4):174-82. PMID: 16474760.
      View in: PubMed
    69. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol. 2004 Dec; 172(6 Pt 1):2244-8. PMID: 15538240.
      View in: PubMed
    70. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Myers RP, Blute ML. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32. PMID: 15371834.
      View in: PubMed
    71. Ly A, Tran NQ, Ward JF, Milligan JR. Repair of oxidative guanine damage in plasmid DNA by indoles involves proton transfer between complementary bases. Biochemistry. 2004 Jul 20; 43(28):9098-104. PMID: 15248767.
      View in: PubMed
    72. Ward JF, Blute ML. Use and timing of radiotherapy in high-risk prostate cancer. JAMA. 2004 Jun 16; 291(23):2817; author reply 2817-8. PMID: 15199027.
      View in: PubMed
    73. Milligan JR, Tran NQ, Ly A, Ward JF. Peptide repair of oxidative DNA damage. Biochemistry. 2004 May 04; 43(17):5102-8. PMID: 15109269.
      View in: PubMed
    74. Young CY, Jatoi A, Ward JF, Blute ML. The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer. Curr Med Chem. 2004 Apr; 11(7):909-23. PMID: 15078173.
      View in: PubMed
    75. Milligan JR, Aguilera JA, Hoang O, Ly A, Tran NQ, Ward JF. Repair of guanyl radicals in plasmid DNA by electron transfer is coupled to proton transfer. J Am Chem Soc. 2004 Feb 18; 126(6):1682-7. PMID: 14871098.
      View in: PubMed
    76. Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol. 2004 Jan-Feb; 22(1):40-7. PMID: 14969803.
      View in: PubMed
    77. Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6. PMID: 14532796.
      View in: PubMed
    78. Ward JF, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep. 2003 Jun; 4(3):196-204. PMID: 12756082.
      View in: PubMed
    79. Ward JF, Blute ML. Chemoprevention of prostate cancer. Expert Rev Anticancer Ther. 2003 Apr; 3(2):203-14. PMID: 12722880.
      View in: PubMed
    80. Gray Sears CL, Ward JF, Sears ST, Puckett MF, Kane CJ, Amling CL. Prospective comparison of computerized tomography and excretory urography in the initial evaluation of asymptomatic microhematuria. J Urol. 2002 Dec; 168(6):2457-60. PMID: 12441939.
      View in: PubMed
    81. Ward JF, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma. J Urol. 2002 Jul; 168(1):56-60. PMID: 12050492.
      View in: PubMed
    82. Kane CJ, Tarman GJ, Summerton DJ, Buchmann CE, Ward JF, O'Reilly KJ, Ruiz H, Thrasher JB, Zorn B, Smith C, Morey AF. Multi-institutional experience with buccal mucosa onlay urethroplasty for bulbar urethral reconstruction. J Urol. 2002 Mar; 167(3):1314-7. PMID: 11832721.
      View in: PubMed
    83. Ward JF. The radiation-induced lesions which trigger the bystander effect. Mutat Res. 2002 Feb 20; 499(2):151-4. PMID: 11827708.
      View in: PubMed
    84. Broaddus WC, Holloway KL, Winters CJ, Bullock MR, Graham RS, Mathern BE, Ward JD, Young HF. Titanium miniplates or stainless steel wire for cranial fixation: a prospective randomized comparison. J Neurosurg. 2002 Feb; 96(2):244-7. PMID: 11838797.
      View in: PubMed
    85. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol. 2001 Nov; 166(5):1688-91. PMID: 11586203.
      View in: PubMed
    86. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001 Nov; 58(5):723-8. PMID: 11711349.
      View in: PubMed
    87. Ward JF, Moquin RR, Maurer ST. Expanding the differential diagnosis of the acute scrotum: ventriculoperitoneal shunt herniation. Urology. 2001 Aug; 58(2):281. PMID: 11489724.
      View in: PubMed
    88. Ward JF, Sands JP, Nowacki M, Amling CL. Malignant cytological washings from prostate specimens: an independent predictor of biochemical progression after radical prostatectomy. J Urol. 2001 Feb; 165(2):469-73. PMID: 11176398.
      View in: PubMed
    89. Ward JF, Cilento BG, Kaplan GW, Velling TE, Puckett M, Stock J. The ultrasonic description of postpubertal testicles in men who have undergone prepubertal orchiopexy for cryptorchidism. J Urol. 2000 May; 163(5):1448-50. PMID: 10751855.
      View in: PubMed
    90. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol. 1999 Oct; 162(4):1307-10. PMID: 10492185.
      View in: PubMed
    91. Gray C, Ward JF, Sands JP. Syncope from increased ventricular response in atrial fibrillation during voiding: a new indication for surgical management in benign prostatic hyperplasia. J Urol. 1999 Feb; 161(2):606-7. PMID: 9915461.
      View in: PubMed
    92. Ward JF, Johnstone PA, Kane CJ. Free-to-total prostate-specific antigen ratios 18-24 months following external beam radiation for adenocarcinoma of the prostate. J Surg Oncol. 1999 Feb; 70(2):91-4. PMID: 10084650.
      View in: PubMed
    93. Ward JF, Kaplan GW, Mevorach R, Stock JA, Cilento BG. Refined microscopic urinalysis for red blood cell morphology in the evaluation of asymptomatic microscopic hematuria in a pediatric population. J Urol. 1998 Oct; 160(4):1492-5. PMID: 9751402.
      View in: PubMed
    94. Ward JF, Friedlander SF, Kaplan GW. Hemangioma presenting as an ulceration of the scrotum. J Urol. 1998 Jul; 160(1):182-3. PMID: 9628647.
      View in: PubMed
    95. Gentle DL, Stoller ML, Jarrett TW, Ward JF, Geib KS, Wood AF. Protease inhibitor-induced urolithiasis. Urology. 1997 Oct; 50(4):508-11. PMID: 9338723.
      View in: PubMed
    96. Ward JF, Nowacki M, Sands JP, Conner RJ, Huisman TK. Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease. J Urol. 1996 Oct; 156(4):1381-4; discussion 1384-5. PMID: 8808876.
      View in: PubMed
    97. Neoadjuvant Systemic Therapy before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity. Clinical Genitourinary Cancer. 14:130-138.
    98. Intratumoral heterogeneity. Cancer.
    99. Focal cryotherapy for localized prostate cancer. Journal of Endourology. 26:100-101.
    100. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. 7:86280-86289.
    101. Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine.
    102. Re. European Urology.
    103. Prostate cancer, PSA, and questions that can only be answered by clinical trials. Oncology. 21.
    104. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. Journal of Urology. 175:1303.
    105. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU International. 117:469-477.
    106. Editorial Comment. Journal of Urology. 176:2031-2032.
    107. Active surveillance monitoring. Asian Journal of Andrology. 17:882-884.
    108. Energies for Focal Ablation. 85-97.
    109. Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. European Urology.
    110. Editorial comment. International Braz J Urol. 29:342-343.
    111. PSA recurrence of prostate cancer. Consultant. 46:1613-1624.
    112. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nature Communications. 7.
    113. Considerations for patient selection for focal therapy. Therapeutic Advances in Urology. 5:330-337.
    114. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 18:276-280.
    115. The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World Journal of Surgical Oncology. 13.
    116. Salvage ablative therapy in prostate cancer. Urologic Oncology: Seminars and Original Investigations. 33:495.e1-495.e7.
    117. Salvage radiotherapy for PSA-only recurrence. American Journal of Urology Review. 3:366-370.
    118. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Canadian Journal of Urology. 23:8271-8277.
    WARD's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description